Skip to content
Screener

Financing Cash Flow at other companies

Pfizer logo
PfizerPFE
-$2.86B+45.4%
Cardinal Health logo
Cardinal HealthCAH
-$483M
McKesson logo
McKessonMCK
$1.63B+38.8%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
-$4.65M-166%
Cencora logo
CencoraCOR
$3.98B
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-$78.5M+90.4%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.77B+129%
Enterprise value$8.21B+77.4%
P/E36.7×-711×
P/S1.9×+1.0×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Tax and other distributions to non-controlling interests(21,067)(24,958)
Proceeds from alliance party510
Acquisition of non-controlling interest(400)
Net cash provided by (used in) financing activities20,306(80,853)
Effect of foreign exchange rate on cash(1,187)(777)
Net decrease in cash, cash equivalents, and restricted cash(173,320)(34,748)
Cash, cash equivalents, and restricted cash - beginning of period312,939118,420
Cash, cash equivalents, and restricted cash - end of period$139,619$83,672

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s financing cash flow?
Amneal Pharmaceuticals, Inc. (AMRX) reported financing cash flow of $79.36M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s financing cash flow changed year-over-year?
Amneal Pharmaceuticals, Inc.'s financing cash flow increased by 290.4% year-over-year, from -$41.69M to $79.36M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s financing cash flow?
Over 2 years (2021 to 2024), Amneal Pharmaceuticals, Inc.'s financing cash flow has grown at a 23.8% compound annual growth rate (CAGR), from -$138.12M to -$211.79M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Amneal Pharmaceuticals, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude